Product

Toludesvenlafaxine

Aliases

Toludesvenlafaxine Hydrochloride Sustained-release Tablet 160mg, Toludesvenlafaxine Hydrochloride Sustained-release Tablet 80mg, Toludesvenlafaxine hydrochloride sustained-release tablets

6 clinical trials

4 indications

Indication

Generalized Anxiety Disorder

Indication

Anhedonia

Indication

Major Depressive Disorder

Indication

Somatic Symptom

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Participants With Generalized Anxiety Disorder.

Status: Recruiting, Estimated PCD: 2026-04-30

Clinical trial

Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder: a Multicentre, Open-label, Parallel-group, Randomised Controlled Trial

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Venlafaxine Hydrochloride Sustained-release Tablets in Patients With Major Depression Disorder: a Multicentre, Open-label, Parallel-group, Randomised Controlled Trial

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

A Single-Arm, Open-Label, Exploratory Mechanistic Validation (PoM) Clinical Trial of Toludesvenlafaxine Hydrochloride Extended-Release Tablets Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain Using 11C-CFT Positron Emission Tomography (PET)

Status: Recruiting, Estimated PCD: 2024-01-31

Clinical trial

Efficacy and Safety of Toluedesvenlafaxine Hydrochloride Extended-release Tablets in Somatic Symptoms of Depression: a Prospective, Single-arm, Multicenter Study

Status: Not yet recruiting, Estimated PCD: 2023-12-01

Clinical trial

A Multicenter, Randomized Withdrawal, Double-blind, Parallel, Placebo-controlled Design Clinical Trial of Toludesvenlafaxine Hydrochloride Extended-Release Tablets

Status: Not yet recruiting, Estimated PCD: 2027-02-28